Jiangsu Kanion Pharmaceutical (600557.SH): Nanjing Kangzhu increased its holdings by 185,200 shares.

Jiangsu Kanion Pharmaceutical (600557.SH) announced that, according to a previous announcement, the company has signed the "Equity Transfer Agreement" and "Supplementary Agreement to the Equity Transfer Agreement" with regard to the earnout clause with the original shareholders of Jiangsu Zhongxin Pharmaceutical Co., Ltd. ("Zhongxin Pharmaceutical"). The original shareholders of Zhongxin Pharmaceutical, Nanjing Kangzhu Enterprise Management Partnership Enterprise (Limited Partnership) ("Nanjing Kangzhu"), received the first installment of the equity transfer payment for their 30% stake in Zhongxin Pharmaceutical, totaling 34.23 million yuan after deduction of taxes, which will be used to increase their holdings in the company on the secondary market. Nanjing Kangzhu was established in May 2024, with the purpose of serving as an equity incentive platform for the management and core team of Zhongxin Pharmaceutical. On February 24, 2025, Nanjing Kangzhu increased its holdings in the company by 185,200 shares through the Shanghai Stock Exchange trading system, representing 0.03% of the total share capital. Nanjing Kangzhu plans to opportunistically increase its holdings of the company's freely tradable A-shares through the Shanghai Stock Exchange trading system in the next 30 days through centralized bidding or block trading. There is no specified price range for this increase plan, with the intended total amount to be 34.23 million yuan (including the amount already acquired in this transaction).